Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ADC Therapeutics SA Common Shares (NY:ADCT)

2.800 +0.130 (+4.87%)
Official Closing Price Updated: 7:00 PM EDT, Jul 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ADC Therapeutics SA Common Shares

< Previous 1 2 3 4 5 Next >
ADC Therapeutics Releases its Inaugural Environmental, Social and Governance Report
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Highlights its Proprietary ADC Platform and Solid Tumor Pipeline
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Participate in Guggenheim Oncology Conference
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Host Webcast Highlighting its ADC Platform and Solid Tumor Pipeline on February 8, 2022
From ADC Therapeutics
Via Business Wire
ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
From ADC Therapeutics
Via Business Wire
ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces Validation of its Marketing Authorization Application by the European Medicines Agency for ZYNLONTA®
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Host Third Quarter 2021 Financial Results Conference Call on November 2, 2021
From ADC Therapeutics SA
Via Business Wire
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma
From ADC Therapeutics
Via Business Wire
ADC Therapeutics Doses First Patient in Phase 1 Clinical Trial of ADCT-901 in Advanced Solid Tumors
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Receives Orphan Drug Designation in Europe for ZYNLONTA®
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Participate in Morgan Stanley’s 19th Annual Global Healthcare Conference
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces Medical Leadership Transition
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Enters Into a Financing Agreement with HealthCare Royalty for Up to $325 Million
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Host Second Quarter 2021 Financial Results Conference Call on August 3, 2021
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces Encouraging Interim Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) Presented at the 16th Annual International Conference on Malignant Lymphoma
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Presents Updated ZYNLONTA™ (loncastuximab tesirine-lpyl) Clinical Data at 16th Annual International Conference on Malignant Lymphoma
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Shareholders Approve All Resolutions at the Annual General Meeting
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces Presentations at the 16th Annual International Conference on Malignant Lymphoma
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Presents Updated Clinical Data at 2021 ASCO Annual Meeting
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Present at Jefferies Virtual Healthcare Conference
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces Online Publication of Camidanlumab Tesirine Phase 1 Results in The Lancet Haematology
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces Presentations at the 2021 ASCO Annual Meeting
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces Receipt of $50 Million Second Tranche of Convertible Credit Facility with Deerfield
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces Online Publication of LOTIS-2 Results in The Lancet Oncology
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.